Drugs / DTPa
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01034514 | Dec 2009 → Jun 2014 | lung cancer | Billy W. Loo Jr. | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT07596199 | Jun → Nov 2026 expected | — | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT00019227 Background | Oct 1996 → Jul 2006 | lymphoma, radiation-induced disorder | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01027845 Background | Dec 2009 → Aug 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00290342 Comparator | Jan 2006 → Jan 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTPa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01027845 ↗ |
| Known as | pentetic acid calcium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019227 ↗ |
| Modality | Vaccine | “GSK Biologicals' combined diphtheria-tetanus-acellular pertussis (DTPa) vaccine” NCT00290342 ↗ |
| Route | Intravenous | “pentetic acid calcium IV over 5 hours” NCT00019227 ↗ |